Investment Research Analysts Opinion: Adamas Pharmaceuticals, Inc. (ADMS), Diana Shipping Inc. (DSX)

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) tinted loss of -2.72% (-0.21 points) to US$7.5. The volume of 0.63 Million shares climbed down over an trading activity of 672.6 Million shares. EPS ratio determined by looking at last 12 month figures is -4.88. Over the same time span, the stock marked US$32.9 as its best level and the lowest price reached was US$7.42. The corporation has a market cap of US$208.8 Million.

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)’s earnings per share has been growing at a -29 percent rate over the past 5 year when average revenue increase was noted as -13.7 percent. The return on equity ratio or ROE stands at -101.5 percent while most common profitability ratio return on investment (ROI) was -55 percent. The company’s institutional ownership is monitored at 0 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 98.1 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 3 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 3 think it is Hold. Recently, analysts have updated the overall rating to 2.17. 5 analysts recommended Overweight these shares while 1 recommended Underweight, according to FactSet data.

Diana Shipping Inc. (NYSE:DSX) is worth US$295.88 Million and has recently risen 4.23% to US$2.71. The latest exchange of 0.4 Million shares is below its average trading activity of 296.64 Million shares. The day began at US$2.61 but the price moved to US$2.61 at one point during the trading and finally capitulating to a session high of US$2.73. The stock tapped a 52-week high of US$5.16 while the mean 12-month price target for the shares is US$3.99.

Currently, the stock carries a price to earnings ratio of 26.57, a price to book ratio of 0.45, and a price to sales ratio of 1.31. For the past 5 years, the company’s revenue has grown 6.6%, while the company’s earnings per share has grown 19.1%. With an institutional ownership near 45.3%, it carries an earnings per share ratio of 0.1.